Evidence map›Paper›PMID 40011416›Full record

ArticleJournal of general internal medicine2025

Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19: Lessons for Future Pandemics.

Yahya Shaikh, Ishaan Gupta, Sophia Purekal, Mary Jane E Vaeth, Maisha Foyez, Charles D Callahan, Maryam Elhabashy, Minahil Cheema, Resham Rahat, James R Ficke and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of general internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trust and Health Equity-Lessons from the COVID- 19 Pandemic.Journal of general internal medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yahya Shaikh *MITRE Corporation, Baltimore, MD, USA.
Ishaan Gupta *Division of Hospital Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. igupta4@jhmi.edu.ORCID 0000-0003-2450-0029
Sophia PurekalDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Mary Jane E VaethBaltimore Convention Center Field Hospital, Baltimore, MD, USA.
Maisha FoyezBaltimore Convention Center Field Hospital, Baltimore, MD, USA.
Charles D CallahanUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Maryam ElhabashyUniversity of Maryland, Baltimore County, MD, USA.
Minahil CheemaUniversity of Maryland School of Medicine, Baltimore, MD, USA.
Resham RahatDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
James R FickeDepartment of Orthopaedic Surgery, Johns Hopkins University, Baltimore, MD, USA.
Albert W WuDepartment of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Paul G AuwaerterThe Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Melinda E KantsiperDivision of Hospital Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Zishan K SiddiquiDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

methodsWe conducted a single-center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021, and May 14, 2021.

resultsAmong the 2406 eligible participants, mAb treatment was significantly underutilized among African American patients compared to White patients (OR 1.8; 95% CI 1.5-2.1). The higher proportion of refusals and cancellations of mAb treatment may suggest a higher level of hesitancy among African American patients (OR 1.7; 95% CI 1.3-2.1).

conclusionEvaluating the reasons and addressing racial disparities in hesitancy of novel therapeutics under Emergency Use Authorization (EUA) offer a critical opportunity to address the inequities in pandemic care.

Indexed as

Antibodies, MonoclonalCOVID-19COVID-19 Drug TreatmentHealthcare DisparitiesPatient Acceptance of Health CareAdultAgedBlack or African AmericanCross-Sectional StudiesFemaleHumansMaleMiddle AgedPandemicsSARS-CoV-2WhiteAntibodies, MonoclonalCOVID-19disparitiesequityhesitancymonoclonal antibodyutilization

Identifiers

PMID40011416
PMCPMC12325127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.